Bausch Health Companies (BHC): Bausch + Lomb Granted FDA 510(K) Clearance for Coating Technology

Coating Technology offers Improved Lens Wettability for Patients with Challenging Vision Needs

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies (BHC), announced it has received 510(k) clearance for use of the Tangible® HydraPEG® custom contact lens coating technology with some of its leading Boston® gas permeable (GP) materials, the Boston XO®, Boston XO2®, Boston EO® and Boston ES® lenses, including those utilized in the Zenlens™ scleral lens family. Designed to address contact lens discomfort and dryness, the Tangible® Hydra-PEG® is a high-water polymer coating that is bonded to the surface of a contact lens. With this coating technology, eye care professionals have the opportunity to enhance contact lens customization for their patients using these Bausch + Lomb lens offerings.

“The approval of the Hydra-PEG coating technology allows eye care professionals to offer improved lens wettability when using some of our key Boston® GP materials or Zenlens™ scleral lenses, which demonstrates our ongoing commitment to bringing advancements that help meet the challenging vision needs of this patient segment,” said Joe Gordon, U.S. President, Bausch + Lomb. “We continue to provide eye care professionals innovative specialty contact lens materials and support through our Boston brand of products, which have been available for decades.”

In June 2018, Bausch + Lomb entered into a worldwide licensing agreement with Tangible Science, LLC, a company whose mission is to create technologies that improve the contact lens wearing experience, to offer the Tangible Science Hydra-PEG® advanced contact lens coating technology on specific materials and lenses from its specialty contact lens business.

“Specialty contact lenses and the ability to offer customizable solutions are important for patients with challenging visual needs,” said Maria K. Walker, O.D., FAAO, FSLS, visiting professor, University of Houston College of Optometry, Houston. “The availability of the Tangible® Hydra-PEG® coating with Bausch + Lomb Specialty Vision Products will enable practitioners to offer patients additional solutions for their demanding visual requirements.”

Analyst Ratings 

TipRanks’ data shows a strong bullish camp backing this drug maker. Bausch Health stock has amassed 6 ‘buy’ ratings in the last three months, with just one ‘sell’ rating. The 12-month average price target stands tall at $33.14, marking nearly 31% in return potential for the stock. (See BHC’s price targets and analyst ratings on TipRanks)


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts